Endo Pharmaceuticals Acquires Par Pharma

According to biospace.com, Endo Pharmaceuticals acquired Par Pharma for $8.05 billion. In the article, the CEO of Endo Pharmaceuticals says: “This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive...

UK Companies Face Rising Payments to DH As A Result of PPRS

The Pharmaceutical Price Regulation Scheme is only into the second year of implementation and already companies are facing rising payments to the Department of Health and may not be reconsidering their options.  According to PharmaPhorum.com, “for 2016 through...